Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID-IRI study.
Erdem H, Kocoglu E, Ankarali H, El-Sokkary R, Hakamifard A, Karaali R, Kulzhanova S, El-Kholy A, Tehrani HA, Khedr R, Kaya-Kalem A, Pandak N, Cagla-Sonmezer M, Nizamuddin S, Berk-Cam H, Guner R, Elkholy JA, Llopis F, Marino A, Stebel R, Szabo BG, Belitova M, Fadel E, Yetisyigit T, Cag Y, Alkan S, Kayaaslan B, Oncu S, Ozdemir M, Yilmaz M, Isik AC, Başkol D, Sincan G, Cascio A, Ozer-Balin S, Korkmaz N, Ripon RK, Abbas S, Dumitru IM, Eser-Karlidag G, Lanzafame M, Rafey A, Raza A, Sipahi OR, Darazam IA, Elbahr U, Erdem I, Ergen P, Bilir C, Caskurlu H, Erdem A, Makek MJ, Altindis M, Lakatos B, Luca CM, Yilmaz EM, Nsutebu E, Cakmak R, Sirmatel F. Erdem H, et al. Among authors: yilmaz m, yilmaz em. Int J Antimicrob Agents. 2023 Sep;62(3):106919. doi: 10.1016/j.ijantimicag.2023.106919. Epub 2023 Jul 7. Int J Antimicrob Agents. 2023. PMID: 37423582
Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: multicentre observational study (CarDINe Study).
Pascale R, Toschi A, Aslan AT, Massaro G, Maccaro A, Fabbricatore D, Dell'Aquila A, Ripa M, Işık ME, Kızmaz YU, Iacopino S, Camici M, Perna F, Akinosoglou K, Karruli A, Papadimitriou-Olivgeris M, Kayaaslan B, Bilir YA, Evren Özcan E, Turan OE, Işık MC, Pérez-Rodríguez MT, Yagüe BL, Quirós AM, Yılmaz M, Petersdorf S, De Potter T, Durante-Mangoni E, Akova M, Curnis A, Gibertoni D, Diemberger I, Scudeller L, Viale P, Giannella M; CarDINe Study Group. Pascale R, et al. Among authors: yilmaz m. Int J Antimicrob Agents. 2023 Mar;61(3):106734. doi: 10.1016/j.ijantimicag.2023.106734. Epub 2023 Jan 21. Int J Antimicrob Agents. 2023. PMID: 36690123 Free article.
Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study.
Aslan AT, Tabah A, Köylü B, Kalem AK, Aksoy F, Erol Ç, Karaali R, Tunay B, Guzeldağ S, Batirel A, Dindar EK, Akdoğan Ö, Bilir Y, Ersöz G, Öztürk B, Selçuk M, Yilmaz M, Akyol A, Akbaş T, Sungurtekin H, Timuroğlu A, Gürbüz Y, Çolak O, Bayindir Y, Eroğlu A, Ferlicolak L, Çeşme U, Dağ O, Buetti N, Barbier F, Ruckly S, Staiquly Q, Timsit JF, Akova M. Aslan AT, et al. Among authors: yilmaz m. J Antimicrob Chemother. 2023 Jul 5;78(7):1757-1768. doi: 10.1093/jac/dkad167. J Antimicrob Chemother. 2023. PMID: 37264485 Free PMC article.
Understanding clinical outcomes and factors influencing mortality in intensive care unit patients with COVID-19-associated candidemia.
Aydın S, Mert A, Yılmaz M, Al Maslamani M, Rahimi BA, Ayoade F, El-Kholy A, Belitova M, Sengel BE, Jalal S, Albayrak A, Alatawi JA, Szabo BG, Ganeshan RS, Nsutebu E, Poojary A, Akkoyunlu Y, Alkan S, Elik DB, Eser-Karlidag G, Santos L, Moroti R, Altın N, Gürbüz E, Ulusoy TÜ, Sipahi OR, Çaşkurlu H, Esmaoğlu A, Lakatos B, El-Sayed NM, Marıno A, Cascio A, Mihai A, Dumitru IM, Pshenichnaya N, Ripon RK, Makek MJ, Rashid N, Baljić R, Dascalu C, Sincan G, Kızmaz YU, Madendere B, Erdem H. Aydın S, et al. Among authors: yilmaz m. Mycoses. 2024 Jan;67(1):e13687. doi: 10.1111/myc.13687. Mycoses. 2024. PMID: 38214425
Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study.
Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M, Aslan AT, Leone M, Conway Morris A, Bassetti M, Arvaniti K, Lipman J, Ferrer R, Qiu H, Paiva JA, Povoa P, De Bus L, De Waele J, Zand F, Gurjar M, Alsisi A, Abidi K, Bracht H, Hayashi Y, Jeon K, Elhadi M, Barbier F, Timsit JF; EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network. Tabah A, et al. Intensive Care Med. 2023 Feb;49(2):178-190. doi: 10.1007/s00134-022-06944-2. Epub 2023 Feb 10. Intensive Care Med. 2023. PMID: 36764959 Free PMC article.
The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections.
Buetti N, Tabah A, Setti N, Ruckly S, Barbier F, Akova M, Aslan AT, Leone M, Bassetti M, Morris AC, Arvaniti K, Paiva JA, Ferrer R, Qiu H, Montrucchio G, Cortegiani A, Kayaaslan B, De Bus L, De Waele JJ, Timsit JF; EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP), and the OUTCOMEREA Network. Buetti N, et al. Intensive Care Med. 2024 Mar 18. doi: 10.1007/s00134-024-07348-0. Online ahead of print. Intensive Care Med. 2024. PMID: 38498170
Switch to oral antibiotics in Gram-negative bacteraemia: a randomized, open-label, clinical trial.
Omrani AS, Abujarir SH, Ben Abid F, Shaar SH, Yilmaz M, Shaukat A, Alsamawi MS, Elgara MS, Alghazzawi MI, Shunnar KM, Zaqout A, Aldeeb YM, Alfouzan W, Almaslamani MA; SOAB Study Group. Omrani AS, et al. Among authors: yilmaz m. Clin Microbiol Infect. 2024 Apr;30(4):492-498. doi: 10.1016/j.cmi.2023.10.014. Epub 2023 Oct 18. Clin Microbiol Infect. 2024. PMID: 37858867 Clinical Trial.
Correction: The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections.
Buetti N, Tabah A, Setti N, Ruckly S, Barbier F, Akova M, Aslan AT, Leone M, Bassetti M, Morris AC, Arvaniti K, Paiva JA, Ferrer R, Qiu H, Montrucchio G, Cortegiani A, Kayaaslan B, De Bus L, De Waele JJ, Timsit JF; EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP), and the OUTCOMEREA Network. Buetti N, et al. Intensive Care Med. 2024 Apr 8. doi: 10.1007/s00134-024-07415-6. Online ahead of print. Intensive Care Med. 2024. PMID: 38587556 No abstract available.
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG; ReSTORE trial investigators. Thompson GR 3rd, et al. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. Lancet. 2023. PMID: 36442484 Free article. Clinical Trial.
3,443 results